These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1075 related articles for article (PubMed ID: 15867261)
1. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Allen TM; Mumbengegwi DR; Charrois GJ Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261 [TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. Cheng WW; Allen TM J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Lopes de Menezes DE; Pilarski LM; Allen TM Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662 [TBL] [Abstract][Full Text] [Related]
4. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Sapra P; Allen TM Cancer Res; 2002 Dec; 62(24):7190-4. PubMed ID: 12499256 [TBL] [Abstract][Full Text] [Related]
5. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Sapra P; Moase EH; Ma J; Allen TM Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990 [TBL] [Abstract][Full Text] [Related]
6. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
7. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
8. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479 [TBL] [Abstract][Full Text] [Related]
10. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Loi M; MarchiĆ² S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382 [TBL] [Abstract][Full Text] [Related]
11. The liposomal formulation of doxorubicin. Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375 [TBL] [Abstract][Full Text] [Related]
12. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
13. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. Mayer LD; Dougherty G; Harasym TO; Bally MB J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330 [TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Li X; Ding L; Xu Y; Wang Y; Ping Q Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296 [TBL] [Abstract][Full Text] [Related]
15. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Laginha KM; Verwoert S; Charrois GJ; Allen TM Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6944-9. PubMed ID: 16203786 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737 [TBL] [Abstract][Full Text] [Related]
17. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Sapra P; Allen TM Clin Cancer Res; 2004 Apr; 10(7):2530-7. PubMed ID: 15073133 [TBL] [Abstract][Full Text] [Related]